Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVT 101 NR2B antagonist effects on cognition and fMRI in healthy males
2007-000986-40Phase 2Completed
- Sponsor
- Evotec SE
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EVT-101 (2 arms), sponsored by Evotec SE. Primary endpoint: Change in fMRI BOLD signal. Started May 2007; status: completed.
02
Drugs
EVT-101
Beyond the preview
Go deeper on 2007-000986-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000986-40.